Vela pharm. Entwicklung u. Laboranalytik GmbH
About Vela pharm. Entwicklung u. Laboranalytik
Vela Laboratories is a GMP-certified contract laboratory offering protein characterisation services (Biopharmaceuticals, Biogenerics, Biologics/Biosimilars) for all stages of product development (pre-clinical, clinical) up to market approval. Vela Laboratories is seeking new customers for its GMP-certified contract laboratory: pharmaceutical and biotech companies that require characterisation of proteins (Biopharmaceuticals, Biogenerics, Biologics / Biosimilars) during the different stages of product development (from the preclinical / clinical stage) up to market approval. Vela Laboratories, headquartered in Vienna, is a privately owned company, initially financed by the founders Markus Fido, Andreas Nechansky, Ralf Kircheis and Armin Franz. Vela is supported by the Austria Wirtschaftsservice (AWS), the Zentrum für Innovation und Technologie (ZIT), and by private investors. Revenues are generated by its contract analysis services.
- Focus : Manufacturer
- Industry : Pharma
Product portfolio of Vela pharm. Entwicklung u. Laboranalytik
News about Vela pharm. Entwicklung u. Laboranalytik
Here you will find Vela pharm. Entwicklung u. Laboranalytik GmbH
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
